Madrigal Pharmaceuticals, Inc.MDGLNASDAQ
Loading
EBITDA Margin Over TimeExpanding
Percentile Rank40
Studio
Year-over-Year Change

EBITDA as a percentage of revenue

Latest
-27.59%
↑ 81% vs avg
Percentile
P40
Within normal range
Streak
1 yr
Consecutive growthExpanding
Average
-142.87%
Historical baseline
PeriodValueYoY Change
TTM-27.59%+89.0%
2024-249.88%-
20220.00%-
20210.00%-
20120.00%+100.0%
2011-579.75%-